Interleukin 6 (IL-6) and soluble IL-2 receptor levels in patients with rheumatoid arthritis treated with low dose oral methotrexate

A Crilly, I B McInness, A G McDonald, J Watson, H A Capell, R Madhok

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

OBJECTIVE: To investigate the effect of oral methotrexate (MTX) on circulating levels of interleukin 6 (IL-6) and soluble IL-2 receptor (sIL-2R) in patients with rheumatoid arthritis (RA).

METHODS: We measured serum concentrations of IL-6 (n = 20) and sIL-2R (n = 16) before MTX therapy and again after 12 weeks.

RESULTS: MTX significantly reduced IL-6 and sIL-2R after 12 weeks of therapy, and although the levels remained low at 24 weeks of therapy, the reduction was not significant. Reduction in cytokine levels was paralleled by an improvement in clinical indices. Placebo treatment did not significantly alter IL-6 or sIL-2R.

CONCLUSION: MTX appears capable of cytokine modulation, although the mechanism is not clear.

Original languageEnglish
Pages (from-to)224-6
Number of pages3
JournalThe Journal of Rheumatology
Volume22
Issue number2
Publication statusPublished - Feb 1995

Keywords

  • Administration, Oral
  • Arthritis, Rheumatoid
  • Dose-Response Relationship, Drug
  • Humans
  • Interleukin-6
  • Methotrexate
  • Middle Aged
  • Receptors, Interleukin-2
  • Solubility

Fingerprint Dive into the research topics of 'Interleukin 6 (IL-6) and soluble IL-2 receptor levels in patients with rheumatoid arthritis treated with low dose oral methotrexate'. Together they form a unique fingerprint.

  • Cite this